Jefferies Financial Group’s Structure Therapeutics GPCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.28M Buy
122,322
+81,697
+201% +$3.83M 0.01% 701
2026
Q2
$2.18M Sell
40,625
-21,967
-35% -$972K 0.01% 664
2026
Q1
$3.02M Sell
62,592
-40,401
-39% -$2.76M 0.02% 474
2025
Q4
$7.16M Sell
102,993
-67,352
-40% -$2.75M 0.04% 407
2025
Q3
$4.77M Buy
+170,345
New +$3.39M 0.02% 383
2025
Q1
– Sell
-2,000
Closed -$54.2K – 1767
2024
Q4
$54.2K Sell
2,000
-5,000
-71% -$177K ﹤0.01% 1495
2024
Q3
$307K Buy
+7,000
New +$271K ﹤0.01% 1109
2024
Q2
– Sell
-2,000
Closed -$85.7K – 1576
2024
Q1
$85.7K Buy
+2,000
New +$84.3K ﹤0.01% 1451

Other funds holding GPCR

Jefferies Financial Group's GPCR Position: Q3 2026 in Review

Jefferies Financial Group increased its Structure Therapeutics (GPCR) stake by 201% in Q3 2026, buying an estimated $3.83M and bringing the position to 122,322 shares worth $1.28M. The position accounts for 0.01% of the portfolio, ranked #701.

Jefferies Financial Group first reported a position in GPCR in Q1 2024 and has held it in 8 quarters since. The position peaked at $7.16M in Q4 2025. 170 funds tracked by Wall St. Rank hold GPCR as of Q3 2026.

  • Jefferies Financial Group held 122,322 shares of Structure Therapeutics worth $1.28M as of Q3 2026.
  • Jefferies Financial Group bought 81,697 Structure Therapeutics shares in Q3 2026, an estimated $3.83M.
  • Structure Therapeutics made up 0.01% of Jefferies Financial Group's portfolio in Q3 2026, its #701 holding.
  • Jefferies Financial Group first reported a position in Structure Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • Jefferies Financial Group's Structure Therapeutics position peaked at $7.16M in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Structure Therapeutics as of Q3 2026.

Based on Jefferies Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.